Brevan Howard Capital Management
LYEL icon

Brevan Howard Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Brevan Howard Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Sell
11,557
-1,878
-14% -$34K ﹤0.01% 1936
2026
Q1 		$270K Buy
+13,435
New +$314K ﹤0.01% 1693
2024
Q1 		– Sell
-1,305
Closed -$50.6K – 1200
2023
Q4 		$50.6K Buy
+1,305
New +$47K ﹤0.01% 994

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Brevan Howard Capital Management's LYEL Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Lyell Immunopharma (LYEL) stake by 14% in Q2 2026, selling an estimated $34K and leaving 11,557 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #1936.

Brevan Howard Capital Management first reported a position in LYEL in Q4 2023 and has held it in 3 quarters since. The position peaked at $270K in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Brevan Howard Capital Management held 11,557 shares of Lyell Immunopharma worth $162K as of Q2 2026.
  • Brevan Howard Capital Management sold 1,878 Lyell Immunopharma shares in Q2 2026, an estimated $34K.
  • Lyell Immunopharma made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1936 holding.
  • Brevan Howard Capital Management first reported a position in Lyell Immunopharma in Q4 2023 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Lyell Immunopharma position peaked at $270K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.